Our unique IND engine has helped us identify novel pathways and targets in immuno-oncology and other areas.

FPA150 is a novel, first-in-class B7-H4 antibody. B7-H4 over-expression is observed in multiple solid tumors, including breast, bladder and gynecologic cancers, and is associated with poor prognosis.

This antibody is designed with dual mechanisms of action:

  • It blocks the T cell checkpoint activity of B7-H4
  • It has been engineered to drive immune-based killing of tumor cells by antibody-dependent cell-mediated cytotoxicity through the recruitment of natural killer cells

We are studying FPA150 as a monotherapy in a Phase 1a/1b clinical trial. In the Phase 1b portion of the trial, we will test FPA150 in patients whose tumors overexpress B7-H4, such as in breast, ovarian and endometrial cancer – indications in which there is high unmet need for immuno-oncology treatments.